We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+29.83%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$219M
AUM Growth
+$63.7M
Cap. Flow
+$40.8M
Cap. Flow %
18.61%
Top 10 Hldgs %
56.75%
Holding
48
New
14
Increased
17
Reduced
2
Closed
15

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$18.4M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$11.7M
3
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$7.65M
4
BDSX icon
Biodesix
BDSX
+$7.46M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.99M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$12.6M
2
QDEL icon
QuidelOrtho
QDEL
+$8.63M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$8.56M
4
CYTK icon
Cytokinetics
CYTK
+$7.37M
5
ILMN icon
Illumina
ILMN
+$6.32M

Sector Composition

Rank Sector Weight
1 Healthcare 97.93%
2 Financials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTRS icon
1
Viatris
VTRS
$20.5B
$21.2M 9.66%
+1,130,504
New +$18.4M
SAGE
2
DELISTED
Sage Therapeutics
SAGE
$15.7M 7.17%
181,650
+79,188
+77% +$5.84M
JAZZ icon
3
Jazz Pharmaceuticals
JAZZ
$15.9B
$14.8M 6.76%
89,889
+78,442
+685% +$11.7M
PODD icon
4
Insulet
PODD
$11.5B
$11.7M 5.32%
45,624
+4,477
+11% +$1.11M
NSTG
5
DELISTED
NanoString Technologies, Inc.
NSTG
$11.6M 5.27%
172,862
+11,609
+7% +$582K
KURA icon
6
Kura Oncology
KURA
$791M
$11.3M 5.16%
346,518
+146,034
+73% +$5.13M
GH icon
7
Guardant Health
GH
$21.4B
$10.2M 4.66%
79,239
+10,376
+15% +$1.19M
BDSX icon
8
Biodesix
BDSX
$218M
$9.66M 4.4%
+23,949
New +$7.46M
LAB icon
9
Standard BioTools
LAB
$345M
$9.27M 4.23%
1,544,904
+566,746
+58% +$3.72M
RCUS icon
10
Arcus Biosciences
RCUS
$3.48B
$9.04M 4.12%
348,408
+219,366
+170% +$5.31M
ARNA
11
DELISTED
Arena Pharmaceuticals Inc
ARNA
$7.78M 3.55%
101,245
+7,937
+9% +$595K
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.5B
$7.73M 3.53%
+88,195
New +$6.99M
CDXS icon
13
Codexis
CDXS
$151M
$6.95M 3.17%
+318,492
New +$5.24M
AVDL
14
DELISTED
Avadel Pharmaceuticals
AVDL
$6.38M 2.91%
955,856
+435,026
+84% +$2.72M
PMVP icon
15
PMV Pharmaceuticals
PMVP
$59.2M
$5.94M 2.71%
96,595
+71,703
+288% +$2.81M
TXG icon
16
10x Genomics
TXG
$6.05B
$5.32M 2.43%
37,587
-5,925
-14% -$860K
BNR
17
Burning Rock Biotech
BNR
$95.5M
$5.03M 2.29%
21,773
+37
+0.2% +$9.93K
ITOS
18
DELISTED
iTeos Therapeutics
ITOS
$4.68M 2.13%
138,384
+80,633
+140% +$2.13M
CCCC icon
19
C4 Therapeutics
CCCC
$385M
$4.62M 2.1%
+139,343
New +$4.04M
FATE icon
20
Fate Therapeutics
FATE
$282M
$4.61M 2.1%
50,709
-62,657
-55% -$3.89M
VTGN icon
21
VistaGen Therapeutics
VTGN
$10.2M
$4.34M 1.98%
+74,660
New +$1.91M
DMRA
22
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.78B
$4.22M 1.92%
+13,494
New +$5.02M
ITCI
23
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.16M 1.89%
+130,654
New +$3.43M
BMY.RT
24
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$3.56M 1.62%
5,152,098
+3,591,771
+230% +$7.65M
STRO icon
25
Sutro Biopharma
STRO
$405M
$3.42M 1.56%
+15,758
New +$2.61M
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Asymmetry Capital Management held 48 positions worth $219M, up 41% from $156M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Asymmetry Capital Management deployed $40.8M of net new capital in Q4 2020, opening 14 new positions and adding to 17 existing holdings. Its largest new stake was Viatris: 1,130,504 shares worth $21.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Fate Therapeutics, an estimated $3.89M trimmed.

  • Asymmetry Capital Management's largest Q4 2020 buy was Viatris: 1,130,504 shares worth $21.2M.
  • Asymmetry Capital Management added most to Jazz Pharmaceuticals in Q4 2020, an estimated $11.7M increase.
  • Asymmetry Capital Management's biggest Q4 2020 reduction was Fate Therapeutics, cutting an estimated $3.89M.
  • Asymmetry Capital Management fully exited Ascendis Pharma A/S in Q4 2020, selling an estimated $12.6M.
  • Asymmetry Capital Management's ten largest holdings make up 57% of its $219M portfolio in Q4 2020.
  • Asymmetry Capital Management opened 14 new positions and closed 15 in Q4 2020.
  • Asymmetry Capital Management's portfolio value rose 41% quarter-over-quarter to $219M.

Based on Asymmetry Capital Management's 13F filing for Q4 2020, filed 11 Feb 2021.